Over the last decade, glucagon-like peptide-1 (GLP-1) analogues and inhibitors of the GLP-1-degrading enzyme dipeptidyl peptidase-4 (DPP-4) have been implemented as treatments for type 2 diabetes [1, 2]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.